IGF-1 LR3 1mg

▎ IGF-1 LR3 Struktrɔ

▎ IGF-1 LR3 Risach

Wetin na di risach bakgrɔn fɔ IGF-1 LR3?

Risich pan IGF-1 LR3 kכmכt frכm di nid fכ כvakom di limitεshכn dεm fכ nεchכral insulin-lεk gכt fכktכ 1 (IGF-1). as di kכl rεgεlεt fכ di sεl gro, difrεns, εn mεtabolism, nεchכral IGF-1 de sho pכtεnshal in tisu ripa, grכw εn divεlכpmεnt stכdi, εn sik intavεnshכn. כltu, i gεt bכku bכku tin dεm: in haf-layf de span כnli fכ awa, we de mek i klia kwik kwik wan in vivo. pan tap dat, i de tayt wan to IGF-binding protin dεm, we de rizulta in lכw prכpכshכn fכ fri, aktv fכm dεm we de strכg fכ εksyεrt sכstayn ifekt dεm. Dis limiteshɔn dɛn bin rili kɔnstrakt in ɛfifikɛshɔn insay ɛkspirimɛnt risach ɛn pɔtɛnɛshɛl aplikeshɔn dɛn, we bin drɛb sayɛnsman dɛn fɔ ɛksplɔrɔ strɔkchɔral modifyed analɔg dɛn wit ɛnhans pefɔmɛns.

wit di advansmεnt dεm na mכlikul bayoloji εn protin εnjinia tεknכlכji dεm, risεch tim dεm bin fכkus fכ prεsis mכdify IGF-1 fכ impruv in prכpati dεm. tru dip stכdi dεm fכ di strכkchכ-fכnshכn rilayshכn fכ IGF-1, risechכr dεm dכn fכ no se modifyushכn na spεsifi k amino asid sayt dεm kin infכlכp in intarakshכn wit binding protin dεm εn rεsεpכta dεm: fכ riples glutamik asid na posishכn 3 wit arginin εn ad 13 amino asid to di N-tεrminכs de ridyus in afiniti fכ IGF-binding protin, we de dכn inaktiv binding fכm dεm we i de εnhans binding fכm dεm to di IGF-1 rεsεpכta. di sem tεm, strכkchכral כptimayzεshכn εkstεnd di mכlikul in mεtabolik saykl in vivo, we kin te i gi IGF-1 LR3 wit 83 amino asid dεm. dis rεsult in af-layf we lכng to 20-30 awa εn aprכksimatli tri tכl inkrεs pan di pכtεns.

Wetin na di mεkanism fכ akshכn fכ IGF-1 LR3?

Sεl Proliferashכn εn Difrεns

stimulashכn fכ di Myoblast Proliferashכn: di tεm we di pikin de divεlכp, IGF-1 LR3 de sכmtεm de protεkt di proliferashכn fכ di skel mכsul mayoblast dεm. fכ egzampl, stכdi dεm pan let-jεstεshכn lεmb fεtus dεn sho se afta wan wik we dεn infuz IGF-1 LR3, di skel mכsul mayoblast proliferashכn rεt dεm sכmtεm inkrεs (P < 0.05). dis de sho se IGF-1 LR3 de akt dayrekt pan mayoblast dεm fכ advans di sεl saykl, we de mek mכr mayoblast dεm fכ enta di proliferativ stet εn dat de gi adishכnal sεlyul sכs dεm fכ mכsul tisu gro εn divεlכpmεnt ^[1]..

infכmeshכn fכlikul divεlכpmεnt: di tεm we di ovarian fisiolכji de, IGF-1 LR3 de tek pat fכ rεgεl fכlikul growth εn divεlכpmεnt. insay wan rat supεrovuleshכn mכdel, kכ-administreshכn fכ IGF-1 LR3 wit gonadotropin dεm fכs inkrεs di ovuleshכn rεt εn εlevεt ovarian wet insay sכm rat strayn dεm. dis sho se IGF-1 LR3 kin infכlכw fכlikul mεchureshכn εn ovuleshכn bay we i de rεgεl granulosa sεl proliferashכn εn difrεns, we de afekt rεprכdaktiv fכnshכn ^[2]..

Rɛgyuleshɔn fɔ Mɛtabolism

Nutrient Acquisition and Utilization: Fכlכ IGF-1 LR3 infushכn in let-jεstεshכn lεmb fεtus, dεn bin obsεv rεdכks כmbilikal kכd amino asid כptek rεt alongsay lכw fetal amino asid kכnsantreshכn, pan כl we di sεm kayn fetal protin tכnכv rεt. dis sho se IGF-1 LR3 kin infכlכw di fetal nyutriεnt כptek εn yutilizeshכn patεn, we de mek i ebul fכ yuz mכr efyushכn fכ di limited nyutriεnt dεm fכ sכpכt כgan-spεsifi k growth pas fכ inkrεs di fetal nyutriεnt saplai tru di plasεnta bכdi fכ fכlכ כ nyutriεnt tכnfכs stimulashכn ^[2]..

fig 1 IGF-1 de inhεbit inflameshn εn i de aksεlεrayt angiojεnεsis via Ras/PI3K/IKK/NF-κB signal path dεm fכ promuot wund hεl ^[3]..

inhibishכn fכ Insulin Sekreshכn: infushכn fכ IGF-1 LR3 כ salin insay let-jεstεshכn fεtal lεmb dεm rεvεl rεdכks plasma insulin kכnsantreshכn in IGF-1 LR3-infuzεd lεmb dεm. Apat fr dat, insulin sekreshכn we dεn bin de du di haypa glycemic klamp εkspεriεns bin dכn kכmpεr wit di kכntrכl dεm. dis sho se IGF-1 LR3 kin akt dayrekt pan pankrεas β-sεl dεm fכ inhεbit insulin sekreshכn. fכda stכdi dεm pan isolεt fetal aylet dεm sho se aylet dεm frכm IGF-1 LR3-infuzed lεmb dεm sho pεrsisεnt lכw insulin sekreshכn in rispכns to in vitro glukכs stimulashכn, we sho se IGF-1 LR3 kin indyuz intrinsik dεfεkt in pankrεas β-sεl dεm, impεri nכmal insulin sekreshכn fכnshכn ^[4,5].

Angiojenεsis Rεgulεshכn

Rol in ovarian angiojenεsis: In bovin luteinized fכlikul angiojεnεsis kכltכr εkspεriεns, dεn invεstigat di ifekt dεm we IGF-1 LR3 gεt pan luteinized fכlikul εndoteyl sεl (EC) nεtwכk dεm εn projεstεron prodakshכn. rizulεt sho limited impak pan EC growth paramita bכt sכm inkrεs pan sεl proliferashכn (3–5%). kכnvεshכn, IGF-1 LR3 εksyεrt difrεnt ifekt pan projεstεron prodakshכn, we di IGF-1 rεsεptכr antagonist picropodophyllin (PPP) sכmtεm rεdכks כl tu di EC grכw paramita dεm εn projεstεron kכnsantreshכn. dis sho se IGF-1 LR3 kin mכdulet vaskulεrayzeshn εn projεstεron prodakshכn insay luteinized fכlikul dεm tru di IGF-1 rεsεpכta signal path, we de mek i de mεnten ovarian fכnshכn εn fεtiliti ^[6]..

Wetin na di aplikeshɔn dɛn fɔ IGF-1 LR3?

Animal Grɔw ɛn Divɛlɔpmɛnt Risach ɛn Aplikeshɔn

fכ mek di pikin כgan gro: insay εkspεriεns wit di let-jεstεshכn ship pikin dεm, we dεn infuz IGF-1 LR3 bכku bכku wan de inkrεs di fetal כgan gכd, we de mek di כgan dεm lεk di at, kidni, splin, εn adrenal gland dεm divεlכp. dis sho se IGF-1 LR3 de ple imכtant rol fכ rεgεl di fetal כgan divεlכpmεnt prכsεs dεm, we de kכntribyut fכ dip כndastandin fכ di fetal gכd εn divεlכpmεnt rεgεl mεkanism dεm. i de gi tiori sכpכt εn prεktikal gayd fכ impruv animal rεprכdaktiv pεrformεns εn εnhans di pikin sכvayv rεt ^[1]..

Stimulation of Skeletal Muscle Myoblast Proliferation: Risach sho se IGF-1 LR3 de stimulate skel mכsul mayoblast proliferashכn. insay fetal ship εkspεriεns, IGF-1 LR3 infushכn makli εnhans mayoblast proliferashכn aktiviti ^[1]..

Dayabitis ɛn Rilat Sik Risach

Evaluating Effects on Insulin Sekreshכn: εkspεriεns dεm we involv IGF-1 LR3 infushכn insay fetal lεmb dεm sho se di fetal plasma insulin kכnsantreshכn dεm dכn dכn. di tεm we dεn bin de du di haypa glycemic klem εkspεriεns, di insulin lεvεl dεm na di IGF-1 LR3-trit fεtal ship dεm bin 66% lכw pas di kכntrol dεm. dis fεnomen de sho se pכtεnshal asosieshכn bitwin IGF-1 LR3 εn insulin sekreshכn, we de gi imכtant klyu fכ stכdi di patכjεnεsis fכ dayabitis εn fכ divεlכp nyu tεrapi stratεji dεm ^[5]..

Kɔrɛleshɔn wit Atletik Pɔfɔmɛnshɔn: Risach pan ilit Izrɛlayt rɔna ɛn swima dɛn sho se IGF1 jin polimɔfism dɛn kɔrɛlat wit sirkuleshɔn IGF1 lɛvɛl, ɛn se di IGF jenɛtik skɔ (IGF-GS) fɔ sprinta dɛn gɛt fɔ du wit atletik pefɔmɛns. Elite sprinta dɛn sho signifyant ay avɛrej IGF-GS skɔ pas nashɔnal-lɛvel sprinta ɛn ay-lɛv shɔt-distans swima. dis sho se di IGF-1 sistεm kin ple implεnt rol insay terrestrial spid sכpכt. Pan ɔl we i nɔ shɔ if dɛn kin yuz IGF-GS fɔ pik di ilit sprinta dɛn kwik kwik wan, i de gi nyu we fɔ pik atlet ɛn tren intavɛnshɔn. fכs risεch kin mek dεn divεlכp mכr tכgεt trenin program fכ εnhans atlet pεrformεns bay we dεn de mכnitor εn analכz IGF-1-rεlatεd mak dεm na atlet dεm ^[7]..

Risach insay Sɛl Bayoloji ɛn Besik Mɛdisin

Sεl Proliferashכn Rεguleshכn Risach: IGF-1 LR3 posεs di kapasiti fכ stimulate sεl proliferashכn. in vitro εkspεriεns dεm de sho in ifektiv stimulashכn fכ NIH 3T3 sεl proliferashכn. dis de rεnd IGF-1 LR3 wan valyu tul fכ invεstigat sεlyul proliferashכn rεguleshכn mεkanism dεm. bay we dεn obsכv di ifekt dεm we IGF-1 LR3 de du pan proliferashכn akraos difrεn sεl layn dεm, di risach dεm kin gεt insayt fכ fכndamεntכl bayolojikal prכsεs dεm lεk sεl saykl rεguleshכn εn signal path dεm, we de gi wan tiori fכwndeshכn fכ stכdi dεm insay כnkכlכji, rigεnεraytiv mεdisin, εn rilayt fild dεm ^[8]..

Apoptosis εn Protein Mεtabolism Risεch: Insay stכdi dεm pan haydrojεn pεrכksayd-trit C2C12 sεl dεm, IGF-1 (inklud in analכg IGF-1 LR3) de mכdulet sεlyul protin sεntez εn dεgradashכn bεlε bay we i de uprεgulεt Pax7, myogenic rεgεdyushכn fכktכ dεm (MRFs), mTOR, εn P70S6K, ridyus MuRF1 εn MAFbx, εn inhεbit apoptosis, we de rεgεl di bεlε bitwin protin sεntesis εn dεgradashכn. dis de kכntribyut fכ dip כndastand di sεl dεm we de liv εn day mεkanism dεm כnda strεs kכndishכn dεm, εn bak di rεgεdyushכn nεtwכk dεm fכ protin mεtabolism, we de gi nyu tכgεt εn insayt fכ di tritmεnt fכ sik dεm we de rilayt ^[9]..

Dɔn

IGF-1 LR3, as sεntetik lכng akt analכg fכ insulin lεk gכt fכktכ 1, de protεkt כgan-spεsifi k growth in fetal hat εn adrenal gland dεm bay we i de aktibכt signal path dεm lεk PI3K/Akt εn MAPK. i de mek di skel mכsul mayoblast proliferashכn εn protin sεntez, i de rεgεl di mεtabolism, i de mεnten di skel mכsul dεm hεlth, εn i de εp fכ rεkכvri frכm εksεsayz-indyus injuri.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Feng L na wan risachman we de pe atɛnshɔn pan di fild fɔ ɛksɛsayz fisiɔlɔji ɛn kadiovaskular wɛlbɔdi. dεn akademik wok mεnli sεntrε pan fכ εksplכr di rεgεdyushכn ifekt dεm fכ difrεn εksεsayz fכm dεm pan fysiolojikal fכnshכn dεm, patikyular di intarakshכn bitwin εksεsayz εn di bכdi in mכlikul mεkanism dεm we riliyt to mכsul hεlth εn kכdivaskyul sik rεkכvεshכn. Bɔku tɛm, Dɔktɔ Fɛng kin tek wan kɔmbaynshɔn pan prɛklinik risach mɔdel ɛn mɔlikul bayoloji tɛknik fɔ du dip stɔdi. Feng L de list in di rεfrεns כf saytεshכn [9].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Stremming J, Wait A, Donthi A, ɛn ɔda pipul dɛn. ship rεkombinεnt IGF-1 de protεkt כgan-spεsifi k growth in fetal ship. Frontiers in Fisiɔlɔji 2022; 13: 954948.DOI: 10.3389/fphys.2022.954948. Di wan dɛn we de wok fɔ di kɔmni.

[2] Khamsi F, Roberge S, Wong J. Novel demonstreshכn fכ wan fysiolojikal/fכmakכlכjik rol fכ insulin-lεk gכt fכktכ-1 in ovulεshכn in rat εn akshכn pan kumulus oophorus. Ɛndɔkrin 2001; 14(2): 175-180.DOI: 10.1385/ENDO: 14: 2:175.

[3] Zhang X, Hu F, Li J, ɛn ɔda pipul dɛn. IGF-1 de inhεbit inflameshn εn aksεlεrayt angiojεnεsis via Ras/PI3K/IKK/NF-κB signal path dεm fכ promuot wund hεlin. Yuropian Jɔnal fɔ Famasiutik Sayns 2024; 200: 106847.DOI: 10.1016/j.ejps.2024.106847. Di wan dɛn we de stɔdi bɔt di Baybul.

[4] Wait A, Stremming J, Boehmer BH, ɛn ɔda pipul dɛn. di ridyus glukכs-stimulεt insulin sekreshכn we de fכlכ 1 wik IGF-1 infushכn insay let jεstεshכn fetal ship dεm na bikoz fכ wan intrinsik aylet dεfεkt. Amɛrikan Jɔnal fɔ Fisiɔlɔji-Ɛndokrinɔlɔji ɛn Mɛtabolism 2021; 320(6): E1138-E1147, ɛn di ɔda wan dɛn. DOI:10.1152/ajpendo.00623.2020. Di wan dɛn we de wok fɔ di kɔmni.

[5] Wait A, Stremming J, Brawn L. D., Rozans P. J., ɛn ɔda pipul dɛn. di atεnuet glukכs-stimulεt insulin sekreshכn di tεm we dεn de infuz di akyu IGF-1 LR3 insay fetal ship dεm nכ de de insay isolεt aylet dεm. Jɔnal fɔ Divɛlɔpmɛnt Ɔrijin fɔ Wɛlbɔdi ɛn Sik 2023; 14(3): 353-361.DOI: 10.1017/S2040 17442300009 0. Di wan dɛn we de stɔdi bɔt di Baybul.

[6] Nwachukwu C. U., Robinson R. S., Woad K. J., ɛn ɔda pipul dɛn. Efεkt כf insulin lεk gכt fכktכ sistεm pan luteinising angiojεnεsis. Riprodakshɔn ɛn Fɛtiliti 2023; 4(2).DOI: 10.1530/RAF-22-0057. Di wan dɛn we de wok fɔ di kɔmni.

[7] Ben-Zaken S, Meckel Y, Nemet D, Eliakim A. Insulin-layk Grɔwth Faktɔ Aks Jɛnɛtik Skɔ ɛn Spɔt Ɛksɛlɛns. Jɔnal fɔ Strɔng ɛn Kɔndishɔn Risach 2021; 35(9): 2421-2426.DOI: 10.1519/JSC.0000000000004102.

[8] Mao W. Ha-levεl εksprεshכn כf lכng chen Arg~3-IGF-1 in Pichia pastoris εn in purifyushכn εn kכntribyushכn. Bulletin fɔ di Akademi fɔ Militari Mɛdikal Sayns 2008. https://api.semanticscholar.org/CorpusID:88212024.

[9] Feng L, Li B, Xi Y, Cai M, Tian Z. Aerobik εksεsayz εn rεsistεns εksεsayz de εliviet skel mכsul atrofi tru IGF-1/IGF-1R-PI3K/Akt path in mays wit mayokardial infarkshכn. Amɛrikan Jɔnal fɔ Fisiɔlɔji-Sɛl Fisiɔlɔji 2022; 322(2): C164-C176.DOI: 10.1152/ajpsɛl.00344.2021.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL DI INFƆMƐSHƆN DISƐMƐNƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.